Guardant Health Guardant360 Tissue

Guardant Health has launched Guardant360 Tissue, an updated version of its prior tissue genotyping assay that now incorporates multiomics analysis including DNA, RNA, AI-powered PD-L1 immunohistochemistry, and genome-wide methylation data. The test is intended to provide researchers and care teams with a more comprehensive view of a patient's cancer.

The test is powered by the Guardant Infinity smart liquid biopsy platform and enables insights beyond what can typically be found using tests that do not incorporate epigenetics. The company said these insights can apply to important classes of therapeutics, such as PARP-inhibitors and immunotherapies, as well as important new classes of therapies in late-stage development. The test also enables classification and subtyping of each individual tumor at a much higher resolution than previously possible.

According to the company the test also requires 92 percent less tissue surface area for analysis than the industry norm. Samples can also be analyzed with 40 percent fewer slides. The assay covers 742 gene, fusions in 367 RNA genes, with the ability to add genome-wide analysis of the tumor methylome. Test results are available in less than two weeks, and the clinical report is covered by Medicare for eligible patients.